Back to top
more

Reata Pharmaceuticals, Inc. (RETA)

(Delayed Data from NSDQ)

$80.41 USD

80.41
117,440

+2.31 (2.96%)

Updated May 3, 2019 04:00 PM ET

After-Market: $80.37 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Reata Pharmaceuticals, Inc. (RETA) Soars 6.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Gilead Sciences (GILD) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Gilead (GILD) delivered earnings and revenue surprises of 11.33% and 12.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Reata Pharmaceuticals, Inc. (RETA) Down 1.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Reata (RETA) Q3 Earnings Beat, Stock Up on Pipeline Updates

by Zacks Equity Research

Reata (RETA) reports a narrower-than-expected loss in the third quarter. Stock rises after RETA states that the FDA did not request additional data on the NDA for omaveloxolone in Friedreich's ataxia.

Reata Pharmaceuticals, Inc. (RETA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 8.09% and 62.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Intercept Pharmaceuticals (ICPT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Intercept (ICPT) delivered earnings and revenue surprises of -159.49% and 2.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Reata (RETA) Up After FDA Scraps AdCom Meeting for NDA Filing

by Zacks Equity Research

The FDA decides not to hold an advisory committee meeting for Reata Pharmaceuticals' (RETA) regulatory filing seeking approval for omaveloxolone in Friedreich's Ataxia.

Reata Pharmaceuticals, Inc. (RETA) Stock Jumps 20.6%: Will It Continue to Soar?

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Reata Pharma (RETA) is Striving Hard Despite Pipeline Setbacks

by Zacks Equity Research

Reata Pharmaceuticals (RETA) is yet to generate product revenues due to the lack of marketed drugs in its portfolio. However, two of its pipeline candidates are close to potential FDA approval.

Why Is Kodiak Sciences Inc. (KOD) Down 23.8% Since Last Earnings Report?

by Zacks Equity Research

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Reata Pharmaceuticals, Inc. (RETA) Up 4.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Reata (RETA) Q2 Earnings Miss, Revenues Down Y/Y, Stock Down

by Zacks Equity Research

Reata (RETA) reports a wider-than-expected loss in the second quarter of 2022, while revenues miss estimates. Stock falls after updates on pipeline programs.

Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -6.32% and 70.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Provention Bio, Inc. (PRVB) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 6.12% and 6.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences (GILD) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Gilead (GILD) delivered earnings and revenue surprises of 4.64% and 6.55%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Why Is Reata Pharmaceuticals, Inc. (RETA) Up 53.1% Since Last Earnings Report?

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Reata (RETA) Up More Than 12% YTD: What's Driving the Rally?

by Zacks Equity Research

Reata's (RETA) prospects are likely to improve following the potential approval of its lead candidate, omaveloxolone, expected by the end of 2022 is likely driving its share price.

Reata (RETA) Friedreich's Ataxia NDA Gets Priority Review

by Zacks Equity Research

Reata (RETA) is seeking approval for omaveloxolone as a treatment for neuromuscular disorder Friedreich's ataxia. The FDA grants priority review to the NDA for the same. Stock rises.

Reata (RETA) Q1 Earnings Top, Omaveloxolone MAA Likely in Q4

by Zacks Equity Research

Reata (RETA) reports a narrower-than-expected loss for the first quarter of 2022 while revenues miss estimates.

Reata Pharmaceuticals, Inc. (RETA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 10.18% and 52.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Kanishka Das headshot

Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More

by Kanishka Das

Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -90.32% and 89.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Reata (RETA) Submits NDA for Friedreich's Ataxia Candidate

by Zacks Equity Research

Reata (RETA) is seeking approval for omaveloxolone as a treatment for neuromuscular disorder Friedreich's ataxia. It completes the rolling submission of an NDA for the same. Stock rises.

Reata Pharmaceuticals, Inc. (RETA) Up 3.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Reata Pharmaceuticals, Inc. (RETA) Stock Jumps 14.5%: Will It Continue to Soar?

by Zacks Equity Research

Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.